Yann Abraham is currently leading the AI for Single Cell initiative, aiming to deliver the true potential of single cell analysis in drug discovery and development, contributing to the identification of new targets and biomarkers through applied machine learning. Previously, Yann was responsible for developing analytical solutions for single-cell proteomics platforms, including mass and flow cytometry, and for analyzing datasets generated in the context of multiple clinical trials. In addition, Yann has collaborated with numerous teams in the context of immuno-oncology, autoimmune disease, and vaccines, developing innovative solutions to visualize and interpret high-dimensional single-cell data.

On joining Janssen, Yann was part of the Discovery Omics team where he was responsible for providing supporting efforts to translate mass cytometry data across many JRD discovery and translational research programs. Prior to joining Janssen, Yann gained experience in exploratory data analysis working for Novartis Pharma AG in Basel, Switzerland, using transcriptomics (microarray and RNAseq) and proteomics data to identify and validate new targets. Yann also collaborated on the analysis of RNAi screens and helped pioneer the adoption of mass cytometry by analyzing the dose-dependent effects of glucocorticoid receptor agonists on macrophage polarization. Before his time at Novartis, Yann worked as a senior scientist for Cellzome AG, in Heidelberg, Germany. In that capacity, Yann has contributed to the development of innovative chemical proteomics solutions, using pan-specific compounds to enrich for specific target classes and estimate compound affinity and selectivity through mass spectrometry.

Yann’s research interests include proteomics, graph-based analysis, and data visualization. He obtained his PhD in 2001 from Université Paris XI in Orsay, France, working on the identification of proteins regulating centrosome duplication in human cells under the supervision of Michel Bornens in the Institut Curie in Paris, France.